Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

Background
Nab-paclitaxel is formulated to address several limitations of paclitaxel.
 
Methods
A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC).
 
Results
Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%).
 
Conclusion
Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel.

Link to Paper >>